EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

[1]  E. Small,et al.  Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Albers,et al.  Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. , 2013, European urology.

[3]  J. Bellmunt.  Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. , 2013, European urology.

[4]  R. Nawroth,et al.  Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer , 2012, BJU international.

[5]  S. Crouzet,et al.  Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[7]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[8]  F. Montorsi,et al.  Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. , 2012, European urology.

[9]  F. Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[10]  P. Scardino,et al.  Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. , 2012, European urology.

[11]  T. Wiegel,et al.  Salvage radiotherapy after prostatectomy - what is the best time to treat? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  F. Montorsi,et al.  Prostate-Specific Antigen Velocity Versus Prostate-Specific Antigen Doubling Time for Prediction of 11C Choline PET/CT in Prostate Cancer Patients With Biochemical Failure After Radical Prostatectomy , 2012, Clinical nuclear medicine.

[13]  E. Galligioni,et al.  Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. , 2012, Urology.

[14]  T. H. Klotz,et al.  Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[16]  M. Picchio,et al.  Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83. , 2011, European urology.

[17]  M. Stöckle,et al.  Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. , 2011, Urologic oncology.

[18]  J. Moul,et al.  A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. , 2011, The Journal of urology.

[19]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[20]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[21]  T. Johansson,et al.  Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15]. , 2011, European urology.

[22]  T. Johansson,et al.  Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. , 2010, European urology.

[23]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[24]  L. Thill,et al.  Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study , 2010, BJU international.

[25]  A. Lipton.  Implications of bone metastases and the benefits of bone-targeted therapy. , 2010, Seminars in oncology.

[26]  G. Di Lorenzo,et al.  Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. , 2010, European urology.

[27]  M. Kattan,et al.  Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology , 2010, BJU international.

[28]  C. McCulloch,et al.  Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. , 2010, Radiology.

[29]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[30]  F. Montorsi,et al.  Testosterone measurement in patients with prostate cancer. , 2010, European urology.

[31]  B. Escudier,et al.  The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. , 2010, European journal of cancer.

[32]  M. Carducci,et al.  A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Faris,et al.  Metabolic sequelae associated with androgen deprivation therapy for prostate cancer , 2010, Current opinion in endocrinology, diabetes, and obesity.

[34]  Donatello Telesca,et al.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Oudard,et al.  Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). , 2010 .

[36]  E. Crawford,et al.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. , 2010, European urology.

[37]  Jan Pruim,et al.  Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. , 2010, International journal of radiation oncology, biology, physics.

[38]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[39]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Sternberg,et al.  Role of targeted therapy in the treatment of advanced prostate cancer , 2010, BJU international.

[41]  M. Perachino,et al.  Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone‐releasing hormone therapy: prognostic significance? , 2010, BJU international.

[42]  J. Dimopoulos,et al.  Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  D. Pfister,et al.  Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. , 2010, European urology.

[44]  Orazio Schillaci,et al.  18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer , 2010, Nuclear medicine communications.

[45]  I. Tannock,et al.  Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[46]  William Berry,et al.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Renshaw,et al.  Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. , 2009, International journal of radiation oncology, biology, physics.

[48]  J. Moul.  Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer , 2009, Cancer.

[49]  B. Leibovich,et al.  Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. , 2009, The Journal of urology.

[50]  D. Dearnaley,et al.  Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? , 2009, Expert review of anticancer therapy.

[51]  C. Na.  Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument. , 2009 .

[52]  A. Bono,et al.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. , 2009, European urology.

[53]  H. Scher,et al.  Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[55]  F. Fazio,et al.  Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. , 2009, European urology.

[56]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.

[57]  J. Chapelon,et al.  Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. , 2009, European urology.

[58]  P. Gabriele,et al.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging , 2009, European Radiology.

[59]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[60]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[61]  K. Shinohara,et al.  Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. , 2008, Urology.

[62]  J. Moul,et al.  Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. , 2008, Critical reviews in oncology/hematology.

[63]  R. Semrau,et al.  Die radikale Salvageprostatektomie , 2008, Der Urologe.

[64]  B. Donnelly,et al.  Salvage prostate cryoablation: initial results from the cryo on-line data registry. , 2008, The Journal of urology.

[65]  L. Collette,et al.  Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). , 2008, European urology.

[66]  A. Pupi,et al.  Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.

[67]  B. Trock,et al.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. , 2008, JAMA.

[68]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Carroll,et al.  Treatment failure after primary and salvage therapy for prostate cancer , 2008, Cancer.

[70]  N. Mottet,et al.  The role of intermittent androgen deprivation in prostate cancer , 2007, BJU international.

[71]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[72]  E. Messing,et al.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Kuban,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Morote,et al.  Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer , 2006, Urologia Internationalis.

[77]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[78]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[79]  L. Collette,et al.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  A. Heidenreich,et al.  Radikale Salvageprostatektomie bei lokalem Prostatakarzinomrezidiv nach Strahlentherapie , 2006, Der Urologe.

[81]  E. Özgür,et al.  [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy]. , 2006, Der Urologe. Ausg. A.

[82]  H. Scher,et al.  Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy , 2005, Clinical Cancer Research.

[83]  J. Eastham,et al.  Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  L. Dogliotti,et al.  Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease , 2005, British Journal of Cancer.

[85]  P. Scardino,et al.  Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. , 2004, The Journal of urology.

[86]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[87]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[88]  M. Soloway,et al.  Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? , 2004, BJU international.

[89]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[90]  Timothy F. Donahue,et al.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2004, The Journal of urology.

[91]  J. Moul,et al.  Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.

[92]  D. Mcleod,et al.  Hormonal therapy: historical perspective to future directions. , 2003, Urology.

[93]  P. Bonnet,et al.  Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. , 2002, Clinical prostate cancer.

[94]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[95]  D. Lubeck,et al.  Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. , 2002, The Journal of urology.

[96]  T. Wilt,et al.  Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. , 2001, The Cochrane database of systematic reviews.

[97]  T. Wilt,et al.  Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. , 2001, Urology.

[98]  Jerome Seidenfeld,et al.  Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer , 2000, Annals of Internal Medicine.

[99]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[100]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  M. Banerjee,et al.  Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.

[102]  T. Tammela,et al.  A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.

[103]  L. Denis,et al.  CasodexTM 10–200 mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer , 1998, European Urology.

[104]  C. Dinney,et al.  The efficacy and complications of salvage cryotherapy of the prostate. , 1997, The Journal of urology.

[105]  P. Walsh,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997 .

[106]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[107]  J. Fiet,et al.  Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). , 1989, The New England journal of medicine.

[108]  R. Santen,et al.  Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  D. Byar,et al.  Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. , 1977, Southern medical journal.

[110]  D. Byar.  The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.

[111]  D. Karnofsky,et al.  A clinical and pathological study of resistance to infection in chronic lymphatic leukemia , 1962, Cancer.

[112]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[113]  Morton Ra,et al.  Commentary on "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". Kantoff PW, Higano CS, Shore ND, Berger , 2011 .

[114]  F. Montorsi,et al.  The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. , 2011, European urology.

[115]  P. Abrahamsson,et al.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. , 2010, European urology.

[116]  A. Serpa Neto,et al.  articleA systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma , 2010 .

[117]  P. Carroll,et al.  Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. , 2009, European urology.

[118]  S. Freedland,et al.  Role of androgen deprivation therapy for node-positive prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  N. C. Cruz Guerra.  Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument. , 2009, Archivos espanoles de urologia.

[120]  P. Iversen,et al.  Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? , 2001, Prostate Cancer and Prostatic Diseases.

[121]  A. V. von Eschenbach,et al.  Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. , 1997, The Journal of urology.